Welcome to our dedicated page for Athira Pharma news (Ticker: ATHA), a resource for investors and traders seeking the latest updates and insights on Athira Pharma stock.
Athira Pharma, Inc. (NASDAQ: ATHA) is a late clinical-stage biopharmaceutical company based in the Seattle, Washington area, dedicated to developing small molecule therapeutics aimed at restoring neuronal health and slowing neurodegeneration. Athira's innovative pipeline includes several promising compounds, particularly targeting the neurotrophic hepatocyte growth factor (HGF) system, which plays a crucial role in nervous system maintenance and repair.
The company’s lead candidate, Fosgonimeton (ATH-1017), is a subcutaneously administered small molecule designed to positively modulate the HGF/MET system. It is currently being evaluated in the Phase 2/3 LIFT-AD clinical trial for the treatment of mild-to-moderate Alzheimer’s disease, with topline data expected in the second half of 2024. Fosgonimeton has shown potential in enhancing neuroprotective, neurotrophic, and anti-inflammatory pathways, which are critical in combating neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease.
In addition to Fosgonimeton, Athira’s pipeline includes ATH-1105 and ATH-1020, both designed to be orally available treatments enhancing the HGF/MET system. ATH-1105 is particularly promising in preclinical models of amyotrophic lateral sclerosis (ALS), demonstrating significant neuroprotective effects, enhanced survival, and improved motor and nerve functions. The company plans to initiate first-in-human studies for ATH-1105 in the first half of 2024.
Athira's research is bolstered by funding from notable organizations such as the Alzheimer’s Drug Discovery Foundation, Washington’s Life Sciences Discovery Fund, and Dolby Family Ventures. This support underscores the company’s strong financial position and its capacity to advance its therapeutic candidates through key development milestones.
Recent updates highlight the therapeutic potential of Athira’s small molecules. For instance, fosgonimeton has demonstrated promising results in preclinical models of Alzheimer’s and Parkinson’s diseases, showing neuroprotective effects and improvement in cognitive and motor functions. Additionally, ATH-1105's preclinical studies have shown consistent beneficial effects in ALS models, reinforcing Athira’s approach and commitment to developing novel therapies for neurodegenerative diseases.
Athira is also active in the scientific community, regularly presenting its findings at major conferences and publishing in peer-reviewed journals. The company’s efforts are focused on leveraging its patented technologies to develop cost-effective treatments that address the root causes of neurodegenerative diseases, setting it apart from competitors that primarily target disease symptoms.
For more information about Athira Pharma, Inc., visit www.athira.com and follow the company on Facebook, LinkedIn, X (formerly known as Twitter), and Instagram.
Athira Pharma (NASDAQ: ATHA) announced the first presentation of preclinical data for its candidate ATH-1020, designed to enhance the hepatocyte growth factor (HGF)/MET system for neuropsychiatric conditions. This data will be presented at the ASENT Annual Meeting from February 28 to March 3, 2022. ATH-1020 aims to address depression-like behaviors and improve cognitive function. The Phase 1 study in healthy volunteers is set to begin in Q1 2022. The company’s lead candidate, fosgonimeton, is also in trials for Alzheimer’s and related diseases.
Athira Pharma announced positive results from a Phase 1 clinical trial of fosgonimeton (ATH-1017) in Alzheimer’s patients. The trial demonstrated a statistically significant improvement in Event-Related Potential (ERP) P300 latency, indicating potential procognitive properties. Fosgonimeton showed a positive safety and tolerability profile across all dosages. The drug has been named by the World Health Organization, enhancing its recognition. Upcoming data from the Phase 2 ACT-AD trial are expected in Q2 2022, showcasing ongoing commitment to developing treatments in neurology.
Athira Pharma (NASDAQ: ATHA) has appointed Grant Pickering to its Board of Directors. Pickering, who has over 30 years in drug development and commercialization, previously served as CEO at Vaxcyte and other firms. Athira's President, Mark Litton, emphasized Pickering's extensive experience as a valuable asset for advancing therapies targeting neurological diseases, including Alzheimer's. Athira’s lead candidate, ATH-1017, aims to restore neuronal health and combat neurodegeneration. The company is currently in late stages of clinical development for innovative therapies.
Athira Pharma (NASDAQ: ATHA) has initiated patient dosing in the SHAPE Phase 2 clinical trial for ATH-1017, targeting Parkinson's disease dementia and Dementia with Lewy bodies. ATH-1017 aims to enhance Hepatocyte Growth Factor (HGF) activity to address neurodegeneration. The randomized trial will enroll 75 participants in the U.S., assessing cognitive, functional, and behavioral endpoints over 26 weeks. Current therapies for these conditions are limited, highlighting a significant need for innovative treatments.
Athira Pharma (NASDAQ: ATHA) reported progress in its clinical programs and outlook for 2022, highlighting the ACT-AD Phase 2 study with topline data expected in 2Q22. The LIFT-AD Phase 3 study of ATH-1017 in Alzheimer's disease is expanding enrollment from 300 to 420 participants to bolster statistical power for secondary endpoints, aiming for top-line data by 1H23. Additionally, the SHAPE Phase 2 trial for Parkinson's disease dementia was initiated, while an IND application for ATH-1020 has been filed. The company anticipates robust developments across its pipeline, focusing on neurodegenerative diseases.
Athira Pharma (NASDAQ: ATHA) announced its third quarter 2021 financial results, highlighting a cash position of $339.4 million. The company completed enrollment in the ACT-AD trial, with topline data expected in H1 2022, while the LIFT-AD trial is actively recruiting, aimed for completion by 2022. R&D expenses rose to $10.7 million compared to $5.8 million in 2020. The net loss increased to $15.7 million ($0.42 per share) from $8.5 million ($1.12 per share) in the same quarter the previous year.
Athira Pharma (NASDAQ: ATHA) announced progress on its late-stage clinical trials for ATH-1017, aimed at treating mild-to-moderate Alzheimer’s disease, during the CTAD conference in Boston. Both trials, ACT-AD and LIFT-AD, are randomized and placebo-controlled, showing balanced baseline characteristics and encouraging safety profiles. Topline data from the ACT-AD trial is expected in the first half of 2022, providing insights on cognitive function and neurodegeneration. The company emphasizes the potential of ATH-1017 in addressing unmet patient needs in Alzheimer's treatment.
Athira Pharma (NASDAQ: ATHA) announces participation in two investor conferences: the Stifel 2021 Virtual Healthcare Conference on November 15 at 2:40 p.m. ET and the Jefferies 2021 London Healthcare Conference available on-demand from November 18 at 4:00 a.m. ET. Both events will feature a fireside chat format. Live webcasts will be accessible through the Investors section of the Athira website, with archived replays available for 30 days. Athira focuses on developing small molecules to restore neuronal health and combat neurodegeneration, particularly in Alzheimer’s and Parkinson’s.
Athira Pharma (NASDAQ: ATHA) announced an upcoming webinar featuring neurologist Dr. John Michael Olichney. The event is scheduled for Friday, Nov. 5, at 9 a.m. PT / 12 p.m. ET, focusing on the P300 latency measure for assessing cognitive function and its correlation with working memory. Key presentations will also include insights from Kevin Church on ATH-1017, a small molecule therapeutic for Alzheimer’s and Parkinson’s dementia, and Hans Moebius on the ongoing ACT-AD trial. The trial's topline data is expected in early 2022.
Athira Pharma (NASDAQ: ATHA) has completed enrollment for its Phase 2 ACT-AD clinical trial, investigating ATH-1017 for mild-to-moderate Alzheimer’s disease. The trial enrolled 77 patients across the U.S. and Australia to evaluate cognitive improvements over 26 weeks. Topline results are expected in the first half of 2022. CEO Mark Litton emphasized the significance of this milestone, noting the potential for ATH-1017 to offer new treatment options. The company also plans to initiate a clinical trial for Parkinson’s disease dementia later this year.
FAQ
What is the current stock price of Athira Pharma (ATHA)?
What is the market cap of Athira Pharma (ATHA)?
What is Athira Pharma, Inc.?
What are Athira's lead compounds?
What is the focus of Athira's research?
When are the next significant milestones for Athira?
Who funds Athira's research?
What differentiates Athira's approach from other companies?
What is Fosgonimeton?
What recent achievements has Athira reported?
How does Athira contribute to the scientific community?
Where can I find more information about Athira Pharma?
